Haemonetics Corp (HAE) reported a significant increase in second-quarter GAAP net income to $38.68 million, or $0.81 per share, up from $33.83 million ($0.66 per share) year-over-year, with adjusted earnings reaching $1.27 per share. This profit growth occurred despite a 5.3% decline in revenue to $327.32 million for the period. The company also issued full-year EPS guidance in the range of $4.80 to $5.00.
Haemonetics Corp (HAE) reported a significant increase in second-quarter GAAP net income, reaching $38.68 million or $0.81 per share, up from $33.83 million or $0.66 per share year-over-year. This profit growth was achieved despite a 5.3% decline in revenue, which fell to $327.32 million from $345.51 million in the prior year period. The company's adjusted earnings for the period stood at $1.27 per share. The divergence between rising profitability and declining top-line revenue suggests potential improvements in operational efficiency, margin expansion, or the impact of non-recurring items, as indicated by the higher adjusted earnings. This bottom-line strength amidst revenue contraction contributes to a moderately positive sentiment for HAE. The company also provided full-year EPS guidance in the range of $4.80 to $5.00, offering a forward-looking perspective on expected performance. This guidance, coupled with the Q2 profit increase, suggests management's confidence in future earnings despite current revenue challenges.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
